

Formulary Update

May 2024

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since March 2024. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions		Indication	Adult Medicines Formulary entry/ rationale	
Aluminium hydroxide		indigestion	1.1.2	Discontinued
Exenatide (Byetta®)		Twice daily preparation for diabetes control	6.1.2.3	Discontinued
Additions		Indication	Adult Medicines Formulary entry/ rationale	
Ivermectin (licensed tablets)		Scabies	13.10.4	Formulary change request
Medroxyprogesterone		Hormonal treatment	6.4.1.2	Formulary change request
Changes in preferred medicines or brand		New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Other changes		Changes made	Adult Medicines Formulary entry/ rationale	
Fosfomycin		Brand name Monuril® removed	5.1.7	now available generically
Clindamycin+benzoyl peroxide gel		Brand name Duac® removed	13.6.1	now available generically
Naloxone		Indication widened to include use in general opioid overdose for both nasal spray and injection	16.2	Formulary change request